Prokidney (PROK) Assets Average (2021 - 2026)
Prokidney's (PROK) quarterly Assets Average came in at $270.9 million in Q2 2026, down 30.38% year-over-year from $389.1 million in Q2 2025, and down 13.78% quarter-over-quarter from $314.2 million in Q1 2026.
Analysis
Prokidney (PROK) Assets Average (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Assets Average for 6 consecutive years, with $270.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Assets Average fell 30.38% year-over-year to $270.9 million in Q2 2026; TTM through Jun 2026 was $270.9 million, a 30.38% decrease from a year earlier, with the FY2025 full-year figure at $388.3 million, down 9.86% from the prior year.
- Assets Average was $270.9 million for Q2 2026 at Prokidney, down from $314.2 million in the prior quarter.
- Over five years, Assets Average peaked at $525.2 million in Q4 2022 and troughed at $145.5 million in Q1 2022.
- A 5-year average of $395.0 million and a median of $413.9 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average soared 260.06% in 2022 and tumbled 30.38% in 2026, its largest moves.
- Over 5 years, Assets Average stood at $525.2 million in 2022, then decreased by 16.95% to $436.2 million in 2023, then increased by 4.99% to $457.9 million in 2024, then fell by 24.97% to $343.6 million in 2025, then slipped by 21.16% to $270.9 million in 2026.
- The last three Assets Average figures came in at $270.9 million (Q2 2026), $314.2 million (Q1 2026), and $343.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 1.45 Bn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 2.69 Bn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 920.60 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 1.67 Bn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 881.90 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 1.43 Bn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 154.46 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.18 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 494.25 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | 270.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 270.90 Mn |
| Mar 31, 2026 | 314.18 Mn |
| Dec 31, 2025 | 343.59 Mn |
| Sep 30, 2025 | 361.87 Mn |
| Jun 30, 2025 | 389.10 Mn |
| Mar 31, 2025 | 423.57 Mn |
| Dec 31, 2024 | 457.93 Mn |
| Sep 30, 2024 | 486.98 Mn |
| Jun 30, 2024 | 443.46 Mn |
| Mar 31, 2024 | 404.16 Mn |
| Dec 31, 2023 | 436.18 Mn |
| Sep 30, 2023 | 468.01 Mn |
| Jun 30, 2023 | 489.69 Mn |
| Mar 31, 2023 | 506.57 Mn |
| Dec 31, 2022 | 525.22 Mn |
| Sep 30, 2022 | 391.72 Mn |
| Jun 30, 2022 | 250.88 Mn |
| Mar 31, 2022 | 145.53 Mn |
| Dec 31, 2021 | 145.87 Mn |
| Sep 30, 2021 | 126.03 Mn |